Market Cap 13.09B
Revenue (ttm) 2.86B
Net Income (ttm) 478.60M
EPS (ttm) N/A
PE Ratio 28.46
Forward PE 20.73
Profit Margin 16.73%
Debt to Equity Ratio 0.00
Volume 1,203,000
Avg Vol 1,165,398
Day's Range N/A - N/A
Shares Out 100.58M
Stochastic %K 54%
Beta 0.35
Analysts Strong Sell
Price Target $182.58

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 858 617 7600
Address:
6027 Edgewood Bend Court, San Diego, United States
GreenDotStocks
GreenDotStocks Apr. 25 at 2:19 PM
New GreenDot Stocks weekly screen update is live. 78 stocks currently qualify. New to the screen: $NBIX $PAC Out: $NXT Upgraded to Green: $TOST $YOU 10 stocks crossed valuation bands this week. Read the full update here: https://www.greendotstocks.com/articles/greendot-stocks-screen-update-week-of-april-25-2026 Then explore every current holding in the GreenDot Stocks screener.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
uptrend2025
uptrend2025 Apr. 22 at 6:46 PM
$ADIL Phase 3 FDA news pending, $60 million royalty agreement with $20 million upfront pending and $NBIX + Adial Pharmaceuticals? 👀
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 21 at 5:24 PM
$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?
1 · Reply
GoIrish1776
GoIrish1776 Apr. 16 at 7:15 PM
$NBIX How's the 7-year return, Kyle?! 7 years! SMH
0 · Reply
GoIrish1776
GoIrish1776 Apr. 16 at 7:13 PM
$NBIX Just embarrassing, Kyle. 7 years of next to NO return! I guess Kevin timed his exit well. Just be patient? Is that the strategy?
0 · Reply
GoIrish1776
GoIrish1776 Apr. 14 at 8:20 AM
$NBIX Get on the train or be under it Kyle! https://www.cnbc.com/2026/04/14/novo-nordisk-openai-ai-drug-discovery-healthcare-nvo.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
InvestKaki
InvestKaki Apr. 12 at 12:00 AM
$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone
0 · Reply
LazyCamel
LazyCamel Apr. 10 at 1:38 PM
$NBIX Q1 as thirty-eight percent of full-year guidance sets up a path where $200M isn't the ceiling — it's the floor if execution continues. Nathaniel T. Bradley
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 8 at 12:38 PM
$NBIX bofa after $SLNO deal model revenues in-line with current SLNO consensus (BofA FY26: $460MN, BofA peak: $1.4BN). Vykat XR contributes $36/sh and net cash now contributes -$2/sh (prev. $25/sh) to new $199 PT prev. $190) 👉Click to view @NasdaqPulse for timely updates amid the volatility.
0 · Reply
Latest News on NBIX
Neurocrine Biosciences Transcript: M&A announcement

Apr 6, 2026, 8:00 AM EDT - 19 days ago

Neurocrine Biosciences Transcript: M&A announcement


Neurocrine to Buy Soleno for $2.9 Billion

Apr 6, 2026, 7:34 AM EDT - 19 days ago

Neurocrine to Buy Soleno for $2.9 Billion

SLNO


Neurocrine to buy Soleno Therapeutics for $2.9 billion

Apr 6, 2026, 7:07 AM EDT - 19 days ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

SLNO


Neurocrine Biosciences Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 2 months ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2025


Neurocrine's movement disorder treatment fails late-stage trial

Dec 22, 2025, 4:50 PM EST - 4 months ago

Neurocrine's movement disorder treatment fails late-stage trial


Neurocrine Biosciences Transcript: R&D Day 2025

Dec 16, 2025, 12:00 PM EST - 4 months ago

Neurocrine Biosciences Transcript: R&D Day 2025


Neurocrine Biosciences to Host R&D Day on December 16

Dec 9, 2025, 4:01 PM EST - 4 months ago

Neurocrine Biosciences to Host R&D Day on December 16


Neurocrine Biosciences Earnings Call Transcript: Q3 2025

Oct 28, 2025, 4:30 PM EDT - 6 months ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2025


Neurocrine Biosciences Earnings Call Transcript: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 9 months ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2025


Neurocrine Biosciences Earnings Call Transcript: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2025


Neurocrine Biosciences Earnings Call Transcript: Q4 2024

Feb 6, 2025, 4:30 PM EST - 1 year ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2024


Neurocrine Biosciences Earnings Call Transcript: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2024


Neurocrine Biosciences Transcript: Study Result

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Neurocrine Biosciences Transcript: Study Result


Neurocrine Biosciences Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2024


Neurocrine Biosciences Earnings Call Transcript: Q1 2024

May 1, 2024, 8:00 AM EDT - 2 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2024


Neurocrine Biosciences Transcript: Stifel Virtual 2024 CNS Day

Mar 19, 2024, 2:00 PM EDT - 2 years ago

Neurocrine Biosciences Transcript: Stifel Virtual 2024 CNS Day


Neurocrine Biosciences Transcript: UBS Virtual CNS Day 2024

Mar 18, 2024, 12:00 PM EDT - 2 years ago

Neurocrine Biosciences Transcript: UBS Virtual CNS Day 2024


Neurocrine Biosciences Earnings Call Transcript: Q4 2023

Feb 7, 2024, 8:00 AM EST - 2 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2023


Neurocrine Biosciences Transcript: Analyst Day 2023

Dec 5, 2023, 1:00 PM EST - 2 years ago

Neurocrine Biosciences Transcript: Analyst Day 2023


Neurocrine Biosciences Earnings Call Transcript: Q3 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2023


Neurocrine Biosciences Transcript: Study Update

Oct 5, 2023, 8:00 AM EDT - 2 years ago

Neurocrine Biosciences Transcript: Study Update


Neurocrine Biosciences Earnings Call Transcript: Q2 2023

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2023


Neurocrine Biosciences Earnings Call Transcript: Q1 2023

May 3, 2023, 8:00 AM EDT - 3 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2023


Neurocrine Biosciences Transcript: Stifel CNS Days

Mar 28, 2023, 12:30 PM EDT - 3 years ago

Neurocrine Biosciences Transcript: Stifel CNS Days


Neurocrine Biosciences Earnings Call Transcript: Q4 2022

Feb 6, 2023, 8:00 AM EST - 3 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2022


Neurocrine Biosciences Earnings Call Transcript: Q3 2022

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2022


Neurocrine Biosciences Earnings Call Transcript: Q2 2022

Aug 3, 2022, 11:03 PM EDT - 4 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2022


Neurocrine Biosciences Earnings Call Transcript: Q1 2022

May 4, 2022, 5:09 AM EDT - 4 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2022


Neurocrine Biosciences Earnings Call Transcript: Q4 2021

Feb 11, 2022, 4:27 PM EST - 4 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2021


Neurocrine Biosciences Earnings Call Transcript: Q3 2021

Oct 31, 2021, 8:00 PM EDT - 4 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2021


Neurocrine Biosciences Earnings Call Transcript: Q2 2021

Aug 3, 2021, 4:30 PM EDT - 5 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2021


Neurocrine Biosciences Earnings Call Transcript: Q1 2021

May 5, 2021, 4:30 PM EDT - 5 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2021


Neurocrine Biosciences Earnings Call Transcript: Q4 2020

Feb 4, 2021, 4:30 PM EST - 5 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2020


Neurocrine Biosciences Earnings Call Transcript: Q3 2020

Nov 9, 2020, 4:30 PM EST - 5 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2020


Neurocrine Biosciences Earnings Call Transcript: Q2 2020

Aug 3, 2020, 4:30 PM EDT - 6 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2020


Neurocrine Biosciences Earnings Call Transcript: Q1 2020

May 6, 2020, 4:30 PM EDT - 6 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2020


Neurocrine Biosciences Earnings Call Transcript: Q4 2019

Feb 4, 2020, 4:30 PM EST - 6 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2019


Neurocrine Biosciences Earnings Call Transcript: Q3 2019

Nov 4, 2019, 4:30 PM EST - 7 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2019


Neurocrine Biosciences Earnings Call Transcript: Q2 2019

Jul 29, 2019, 4:30 PM EDT - 7 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2019


Neurocrine Biosciences Earnings Call Transcript: Q1 2019

Apr 29, 2019, 4:30 PM EDT - 7 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2019


Neurocrine Biosciences Earnings Call Transcript: Q4 2018

Feb 5, 2019, 4:30 PM EST - 7 years ago

Neurocrine Biosciences Earnings Call Transcript: Q4 2018


Neurocrine Biosciences Transcript: Status Update

Jan 29, 2019, 8:00 AM EST - 7 years ago

Neurocrine Biosciences Transcript: Status Update


Neurocrine Biosciences Transcript: Status Update

Dec 12, 2018, 8:30 AM EST - 8 years ago

Neurocrine Biosciences Transcript: Status Update


Neurocrine Biosciences Earnings Call Transcript: Q3 2018

Nov 5, 2018, 4:30 PM EST - 8 years ago

Neurocrine Biosciences Earnings Call Transcript: Q3 2018


Neurocrine Biosciences Earnings Call Transcript: Q2 2018

Jul 31, 2018, 4:30 PM EDT - 8 years ago

Neurocrine Biosciences Earnings Call Transcript: Q2 2018


Neurocrine Biosciences Earnings Call Transcript: Q1 2018

Apr 30, 2018, 5:00 PM EDT - 8 years ago

Neurocrine Biosciences Earnings Call Transcript: Q1 2018


GreenDotStocks
GreenDotStocks Apr. 25 at 2:19 PM
New GreenDot Stocks weekly screen update is live. 78 stocks currently qualify. New to the screen: $NBIX $PAC Out: $NXT Upgraded to Green: $TOST $YOU 10 stocks crossed valuation bands this week. Read the full update here: https://www.greendotstocks.com/articles/greendot-stocks-screen-update-week-of-april-25-2026 Then explore every current holding in the GreenDot Stocks screener.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
uptrend2025
uptrend2025 Apr. 22 at 6:46 PM
$ADIL Phase 3 FDA news pending, $60 million royalty agreement with $20 million upfront pending and $NBIX + Adial Pharmaceuticals? 👀
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 21 at 5:24 PM
$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?
1 · Reply
GoIrish1776
GoIrish1776 Apr. 16 at 7:15 PM
$NBIX How's the 7-year return, Kyle?! 7 years! SMH
0 · Reply
GoIrish1776
GoIrish1776 Apr. 16 at 7:13 PM
$NBIX Just embarrassing, Kyle. 7 years of next to NO return! I guess Kevin timed his exit well. Just be patient? Is that the strategy?
0 · Reply
GoIrish1776
GoIrish1776 Apr. 14 at 8:20 AM
$NBIX Get on the train or be under it Kyle! https://www.cnbc.com/2026/04/14/novo-nordisk-openai-ai-drug-discovery-healthcare-nvo.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
InvestKaki
InvestKaki Apr. 12 at 12:00 AM
$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone
0 · Reply
LazyCamel
LazyCamel Apr. 10 at 1:38 PM
$NBIX Q1 as thirty-eight percent of full-year guidance sets up a path where $200M isn't the ceiling — it's the floor if execution continues. Nathaniel T. Bradley
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 8 at 12:38 PM
$NBIX bofa after $SLNO deal model revenues in-line with current SLNO consensus (BofA FY26: $460MN, BofA peak: $1.4BN). Vykat XR contributes $36/sh and net cash now contributes -$2/sh (prev. $25/sh) to new $199 PT prev. $190) 👉Click to view @NasdaqPulse for timely updates amid the volatility.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 8 at 1:13 AM
The 1st attachment shows the collective $NBIX & $SLNO analyst consensus revenue ests as of the morning the M&A exit was announced incl highest analyst est, consensus, lowest analyst est, consensus excl the highest analyst est, & consensus excl both the highest & lowest analyst est. At the bottom we simply add the 2 together for an idea of what NBIX analyst ests may, again may, look like post M&A. We then show a "what-if" NBIX was acquired for a peer 0.35X multiple on 10-year collective consensus just for fun. This may be absurd considering SLNO exited at a 0.15X 10-year multiple. The graph compares the collective NBIX/SLNO 10-year analyst consensus & an assumed gross margin @ 97% (NBIX actual FY25 gross margin = 97%, SLNO = 99%) v. the actual 10-year revenue & gross margin projection prepared by $SGEN when SGEN was acquired for an EV of $42B. SGEN provided a 12 year forecast (projecting peak sales in Year 10). Compare NBIX/SLNO 10 year gross margin (even if too high) to SGEN $XBI $IBB
1 · Reply
erevnon
erevnon Apr. 7 at 2:40 PM
Wedbush maintains Neurocrine Biosciences $NBIX at Outperform and raises the price target from $151 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
PickAlpha
PickAlpha Apr. 7 at 11:57 AM
PickAlpha Morning Report - Company News: 2026.04.07 News Analysis - 1/3: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53.00 per share in cash via tender offer, with no financing condition and a $95.25 mn termination fee. | View: The binding $53.00 all-cash tender with no financing condition is positive… $NBIX $SLNO $XBI $IBB
0 · Reply
Quantumup
Quantumup Apr. 7 at 11:53 AM
TD Cowen🏁 $MPLT at a Buy rating. $BMY $NBIX BTAI VNDA ABBV TEVA AXSM TD Cowen said in its initiation report: Maplight is advancing candidates for the treatment of CNS and neuropsych conditions. Lead asset ML-007C MA looks to improve upon Cobenfy's profile in the treatment of schizophrenia with Ph. Il data set for Q3. A Ph. Il study in Alzheimer's psychosis would expand the therapy's opportunity. ML-004 is in a Ph. Il study for ASD (Q3:26 data). We see shares as undervalued for schizophrenia alone. Buy.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 6 at 11:54 PM
$SLNO M&A enterprise value of $2.44B appears to be priced @ the lowest Year 4 & 10-year revenue multiples in recent history (of course analyst estimates may not be credible). SLNO was acquired for $0.2B more than DAWN's EV. Analysts forecast SLNO to generate roughly $10B more revenues over the next 10 years than $DAWN ? SLNO was acquired for 1.7X FY29 (Year 4) analyst consensus. Centerview cited the lowest peer Year 4 M&A revenue multiple was 2.25X (though an oncology focused trx). See yesterday's post. We'd remind investors SLNO generated 99% gross margins on Vykat sales in FY25. SLNO was acquired for 0.15X 10-year analyst consensus. We recall ZGNX & SWTX exiting at the lowest 10-year multiples of 0.25 & 0.26X, respectively. Most peer M&A exits are priced @ 0.30-0.40X 10-year revenues per the acquiree mgmt/BOD $NBIX closed at 3.1X. If SLNO FY29 consensus is credible then, because no stock was issued, this s/b quite accretive to NBIX shareholders This is not investment advice $XBI $IBB
2 · Reply
theflynews
theflynews Apr. 6 at 8:39 PM
What You Missed On Wall Street On Monday - $NBIX - https://thefly.com/NBIX
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 6 at 8:07 PM
Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen $NBIX $SLNO https://stocktwits.com/news/equity/markets/neurocrine-soleno-deal-garners-wall-street-praise/cZJ4wmmRIYV
0 · Reply
Quantumup
Quantumup Apr. 6 at 6:15 PM
Oppenheimer⬆️ $NBIX's PT to $220 and reiterated at an Outperform rating. $SLNO $RYTM RLMD HRMY Oppenheimer said—We see NBIX's acquisition of SLNO as an ideal example of NBIX's industry-leading BD expertise considering the attractive ~$2.9B transaction value relative to the large and synergistic opportunity with Vykat XR for Prader-Willi Syndrome (PWS). Vykat remains the first and only FDA-approved therapy for hyperphasia in PWS patients with ~$190M in 2025, only three quarters into launch, and we anticipate NBIX to leverage its medical and commercial infrastructure for Crenessity and Ingrezza to accelerate sales. We also view Vykat as competitively well-positioned considering the unique MOA and historical difficulty for other PWS drug candidates, while expected IP protection extends into the mid-2040s. We add Vykat to our model with our estimated ~$270M sales for 2H26 post-close reaching >$2.3B at peak, driving our new $220 PT (from $192).
0 · Reply
briefingcom
briefingcom Apr. 6 at 3:38 PM
$NBIX: Neurocrine Biosciences is making a strategic move into rare disease, adding a differentiated growth asset with a long runway. Pushback reflects concerns around deal structure, financing, and execution in a new category. See our full analysis: https://www.briefing.com/story-stocks/archive/2026/4/6/-neurocrine-biosciences-bets-on-vykat-xr-growth-with-soleno-buy-shares-dip-on-deal-concerns-(nbix)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $SLNO #soleno #Biotech
0 · Reply
GoIrish1776
GoIrish1776 Apr. 6 at 2:49 PM
0 · Reply
prismmarketview
prismmarketview Apr. 6 at 1:54 PM
Soleno Therapeutics $SLNO surged 30%+ premarket following reports of a potential $2.5B+ acquisition by Neurocrine $NBIX. The deal highlights growing interest in rare disease assets, with Soleno’s Prader-Willi syndrome therapy at the center of the discussion. https://prismmarketview.com/companies/soleno-therapeutics-inc/
0 · Reply
mikesterz7
mikesterz7 Apr. 6 at 1:51 PM
$SLNO $NBIX Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc. today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.
0 · Reply